<?xml version="1.0" encoding="UTF-8"?>
<p>Taken together, the data presented here on the efficacy of remdesivir in prophylactic and therapeutic treatment regimens, the difficulty of coronaviruses to acquire resistance to remdesivir (
 <xref rid="r9" ref-type="bibr">9</xref>), and the availability of human safety data warrant testing of the efficacy of remdesivir treatment in the context of a MERS clinical trial. Our results, together with replication inhibition by remdesivir of a wide range of coronaviruses in vitro and in vivo (
 <xref rid="r7" ref-type="bibr">7</xref>), may further indicate utility of remdesivir against the novel coronavirus 2019-nCoV emerging from Wuhan, China (
 <xref rid="r26" ref-type="bibr">26</xref>).
</p>
